Ubiquitin

The ubiquitin-proteasome system (UPS) targets numerous cellular proteins for degradation. It is a highly complex, temporally controlled, and tightly regulated process that plays major roles in a variety of basic cellular processes[1]. Degradation of a protein via the ubiquitin-proteasome pathway involves two discrete and successive steps: (1) tagging of the substrate by covalent attachment of multiple ubiquitin molecules to synthesize the polyubiquitin chain proteolytic signal and (2) degradation of the tagged protein by the 26S proteasome complex with release of free and reusable ubiquitin catalyzed by ubiquitin-recycling enzymes (DUBs)[2]. Conjugation of ubiquitin to the protein substrate proceeds via a three-step cascade mechanism. Initially, the ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-requiring reaction resulting in a high-energy thiol ester intermediate. Subsequently, this intermediate is transferred to a member of the ubiquitin-carrier proteins family of enzymes, E2 (also known as a ubiquitin-conjugating enzyme [UBC]). Finally, from E2, the activated ubiquitin moiety is attached to the substrate that is specifically bound to an E3, a member of the ubiquitin-protein ligase family of proteins[3]. By successively adding additional activated ubiquitin moieties to internal Lys residues on the previously conjugated ubiquitin molecule, a polyubiquitin chain is synthesized. The degradation signal that is recognized by the 26S proteasome complex is made of a Lys48 polyubiquitin chain. In contrast, monoubiquitination or polyubiquitination with chains linked together via Lys63 serve as nonproteolytic signals in intracellular trafficking, DNA repair, activation of transcription and other signal transduction pathways[4].


[1] Drug discovery in the ubiquitin–proteasome system. G. Nalepa, M. Rolfe, J.W.Harper. Nature Reviews Drug Discovery2006, 5, 596-613.
[2] Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Y Ling et al. Clin. Cancer Res. 2003, 9, 1145-1154.
[3] R.J. Deshaies, C.A.P. Joazeiro. RING Domain E3 Ubiquitin Ligases. Annu. Rev. Biochem. 2009, 78, 399-434.
[4] The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg. A.Ciechanover, P. Brundin. Neuron 2003, 40, 427–446.

Items 1 to 15 of 21 total

per page
Page:
  1. 1
  2. 2
Axon ID Name Description From price
1810 Bortezomib Inhibitor of 26S proteasome €85.00
2935 COH000 First-in-class, highly specific, covalent allosteric inhibitor of SUMO E1 €175.00
1798 Eeyarestatin I Inhibitor of endoplasmic reticulum associated protein degradation (ERAD) €80.00
2449 LDN 57444 Reversible, competitive inhibitor of UCH-L1 deubiquitinase €95.00
1869 MG 132 Inhibitor of 26S proteasome €95.00
2309 ML 323 Selective, reversible and potent inhibitor of the USP1–UAF1 deubiquitinase complex €95.00
2995 ML 367 Inhibitor of ATAD5 stabilization  Recently added €125.00
2678 ML364 Inhibitor of the deubiquitinase USP2 €125.00
2556 MLN 2238 Selective and reversible 20S proteasome inhibitor €85.00
2557 MLN 9708 Citrate prodrug of MLN 2238, selective and reversible 20S proteasome inhibitor €95.00
2565 N106 Activator of E1 ligase mediated SERCA2a SUMOylation €95.00
2228 NSC 687852 Inhibitor of 19S regulatory-particle–associated deubiquitinases (DUBs: UCHL5 and USP14) €90.00
2199 ONX 0914 Selective inhibitor of LMP7 subunit of the immunoproteasome. €95.00
2011 P 005091 Inhibitor of deubiquitinase USP7 and USP47 €95.00
1906 P 22077 Inhibitor of deubiquitinase USP7 and USP47 €95.00

Items 1 to 15 of 21 total

per page
Page:
  1. 1
  2. 2
Please wait...